 |
|
Tiny but toxic: MBL researchers discover a mechanism of neurodegeneration in Alzheimer's disease
March 27, 2009WOODS HOLE, MA-Tiny, toxic protein particles severely disrupt neurotransmission and inhibit delivery of key proteins in Alzheimer's disease, two separate studies by Marine Biological Laboratory (MBL) researchers have found.
The particles are minute clumps of amyloid beta, which has long been known to accumulate and form plaques in the brain of Alzheimer's patients.
"These small particles that haven't aggregated into plaques-these are increasingly being seen as the really toxic species of amyloid beta," says Scott Brady of University of Illinois College of Medicine, who has been an MBL investigator since 1982.
Brady and his colleagues found that these particles inhibit neurons from communicating with each other and with other target cells in the body.
"The disease symptoms for Alzheimer's are associated not with the death of the neurons - that is a very late event - but with the loss of functional connections. It's when the neuron is no longer talking to its targets that you start to get the memory deficits and dementia associated with the disease," Brady says.
The amyloid beta particles activate an enzyme, CK2, which in turn disrupts the "fast axonal transport" system inside the neuron, Brady found. This transport system has motor proteins that move various kinds of cargo (including neurotransmitters and the associated protein machinery for their release) from place to place in the neuron on microtubule tracks.
Brady's findings are complemented by a new study by Rudolfo Llinás of New York University School of Medicine. Brady and Llinás both conduct neuroscience research at the MBL using the giant nerve cell of the Woods Hole squid, Loligo paeleii, as a model system.
Llinás found that activation of CK2 blocks neurotransmission at the synapse - the point where the neuron connects to its target.
"Disruptions in the fast axonal transport system are probably key elements in the pathogenesis of Alzheimer's and other adult-onset neurodegenerative diseases, such as Parkinson's and ALS," says Brady. "It doesn't mean that is the only thing going on, or that it is the triggering feature of the disease. But we do know that changes in the fast axonal transport system are sufficient to cause the 'dying back' of neurons that is characteristic of these diseases."
The new findings suggest the possibility of designing a drug to inhibit CK2 activation in Alzheimer's patients. However, a prior study by Brady found that activation of another enzyme, GSK3, in Alzheimer's also disrupts the fast axonal transport system. It may therefore be necessary to inhibit both enzymes.
"There haven't yet been any therapies designed for Alzheimer's with the idea of protecting the fast axonal transport system," says Brady. "But if there were, they would have to inhibit the activation of both CK2 and GSK3. We can't think of it as a single thing going wrong. There are several things going wrong."
Marine Biological Laboratory
Brady and his colleagues found that these particles inhibit neurons from communicating with each other and with other target cells in the body.
"The disease symptoms for Alzheimer's are associated not with the death of the neurons - that is a very late event - but with the loss of functional connections. It's when the neuron is no longer talking to its targets that you start to get the memory deficits and dementia associated with the disease," Brady says.
The amyloid beta particles activate an enzyme, CK2, which in turn disrupts the "fast axonal transport" system inside the neuron, Brady found. This transport system has motor proteins that move various kinds of cargo (including neurotransmitters and the associated protein machinery for their release) from place to place in the neuron on microtubule tracks.
Brady's findings are complemented by a new study by Rudolfo Llinás of New York University School of Medicine. Brady and Llinás both conduct neuroscience research at the MBL using the giant nerve cell of the Woods Hole squid, Loligo paeleii, as a model system.
Llinás found that activation of CK2 blocks neurotransmission at the synapse - the point where the neuron connects to its target.
"Disruptions in the fast axonal transport system are probably key elements in the pathogenesis of Alzheimer's and other adult-onset neurodegenerative diseases, such as Parkinson's and ALS," says Brady. "It doesn't mean that is the only thing going on, or that it is the triggering feature of the disease. But we do know that changes in the fast axonal transport system are sufficient to cause the 'dying back' of neurons that is characteristic of these diseases."
The new findings suggest the possibility of designing a drug to inhibit CK2 activation in Alzheimer's patients. However, a prior study by Brady found that activation of another enzyme, GSK3, in Alzheimer's also disrupts the fast axonal transport system. It may therefore be necessary to inhibit both enzymes.
"There haven't yet been any therapies designed for Alzheimer's with the idea of protecting the fast axonal transport system," says Brady. "But if there were, they would have to inhibit the activation of both CK2 and GSK3. We can't think of it as a single thing going wrong. There are several things going wrong."
Marine Biological Laboratory
Neurodegeneration Current Events and Neurodegeneration News RSSStatins show dramatic drug and cell dependent effects in the brain
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia.
Trembling hands and molecular handshakes
Fragile X tremor/ataxia syndrome (FXTAS) is a recently recognized condition, which is actually one of the most prevalent heritable neurodegenerative diseases.
Alzheimer's researchers find high protein diet shrinks brain
One of the many reasons to pick a low-calorie, low-fat diet rich in vegetables, fruits, and fish is that a host of epidemiological studies have suggested that such a diet may delay the onset or slow the progression of Alzheimer's disease (AD).
Study examines treatment for olfactory loss after viral infection
Treatment with a glucocorticoid medication, either alone or in combination with Ginkgo biloba, appears to significantly improve the sense of smell in individuals with previous olfactory loss due to upper respiratory infections.
How Proteins Talk to Each Other
Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins).
Reactive Oxygen's Role in Metastasis
Researchers at the Burnham Institute for Medical Research (Burnham) have discovered that reactive oxygen species, such as superoxide and hydrogen peroxide, play a key role in forming invadopodia, cellular protrusions implicated in cancer cell migration and tumor metastasis.
New Insights Into Cardiac Aging
Investigators at Burnham Institute for Medical Research (Burnham) have found that the conserved protein d4eBP modulates cardiac aging in Drosophila (fruit flies).
When Proteins Change Partners
Dieter Wolf, M.D., and colleagues at Burnham Institute for Medical Research (Burnham) have illuminated how competition between proteins enhances combinatorial diversity during ubiquitination (the process that marks proteins for destruction).
Prolonged stress sparks ER to release calcium stores and induce cell death in aging-related diseases
Study shows prolonged stress sparks ER to release calcium stores and induce cell death in aging-related diseases such as atherosclerosis, diabetes and neurodegeneration.
Canadian research breakthrough holds promise for development of effective cancer therapies
Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.
More Neurodegeneration Current Events and Neurodegeneration News Articles
 |
Metal-based Neurodegeneration: From Molecular Mechanisms to Therapeutic Strategies by Robert Crichton (Author), Roberta Ward (Author) This exciting new book opens a window into the causes of debilitating neurological disorders such as Parkinson’s disease, CJD and Huntington’s disease, and gives indications of the prospects for therapy, based on the understanding of molecular defects involved in these diseases. Looking at each specific neurological disorder in turn, the book outlines the role of metals in human biology, in particular in the brain and explores tools for testing potential therapeutic strategies. It concludes with an overview of the potential of both chelation and antioxidant therapy and outlines some perspectives for the future. |
 |
Advances in Research on Neurodegeneration: Volume 10 (Advances in Research on Neurodegeneration, 10) by R. Horowski (Editor), Y. Mizuno (Editor), C.W. Olanow (Editor), W. Poewe (Editor), P. Riederer (Editor), J.A. Stoessel (Editor), M.B.H. Youdim (Editor) Neurobiotec, Berlin, Germany. Presents the proceedings from the 10th International Winter Conference on Neurodegeneration, held in Berlin, Germany, February 14-16, 2002. |
 |
Neurodegeneration Methods and Protocols (Methods in Molecular Medicine) by Jean Harry (Editor), Hugh A. Tilson (Editor) Techniques for studying many aspects of nervous system cell biology. Contains notes about potential pitfalls and tips on how to avoid failures. Modified-outline format. DNLM: Nerve Degeneration. |
 |
New Perspectives on Brain Cell Damage, Neurodegeneration and Neuroprotective Strategies 2007 by Editor-in-Chief: Abel Santamaria (Author), Associate Editor: Maria Esther Jimenez-Capdeville (Author), Editor-in-Chief: Abel Santamaria (Editor) From the Preface For the last four decades, the study of the functioning and pathological alterations of the Nervous System has been intensified in search for therapeutic alternatives against neurodegenerative disorders in humans. Since their first descriptions in the 19th and 20th centuries, sufficient clinical and experimental findings contributed to describe the origin of some of the most common and frequent neurological diseases. Derived from this multidisciplinary research performed along decades, now we know that a great number of factors trigger nerve tissue damage and cell death, and they include the environmental exposure to toxicants, inheritance patterns, the individual susceptibility to endogenous or exogenous neurotoxins, ageing processes, traumatic injury, drug... |
 |
Progress in Neurodegeneration: The Role of Metals (Neurodegenerative Diseases-Laboratory and Clinical Research Series) by Maria Rosa Avila-Costa (Editor), Veronica Anaya Martinez (Editor) This book highlights the role of some metals which induce oxidative stress and imbalances in the neurodegenerative diseases such as Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, Huntington Disease, and other dementias. The chemistry and biochemistry of metals induced-oxidative stress, protein damage is first described, followed by the evidence for a pathological role of oxidative stress in these disease states. It is tempting to speculate that free radical oxygen chemistry contributes to pathogenesis in all these conditions, though it is as yet undetermined what types of oxidative changes occur early in the disease, and what types are secondary manifestations of neuronal degeneration. Finally the authors review different metals to describe their specific role in the... |
 |
Studies on plasticity and neurodegeneration in rat hippocampus: The hippocampus, a brain component important for memory but vulnerable to stressors by Miou Zhou (Author) Hippocampus plays an essential role in learning and memory. Numerous studies have been directed at understanding the mechanisms underlying these processes. In particular, the role of protein synthesis has been extensively debated. Hippocampus is also extremely vulnerable to numerous stressors including excitotoxicity and stroke, and the mechanisms underlying vulnerability of hippocampal neurons to stress are still not completely understood. Studies here are concerned with both problems. Activity-dependent activation of excitatory synapses results in cell membrane depolarization, calcium influx, brief activation of calcium-dependent signaling cascades, changes in dendritic cytoskeleton and protein synthesis; on the other hand, excessive activation of excitatory synapses ... |
 |
Bioimaging in Neurodegeneration (Contemporary Neuroscience) by Patricia A. Broderick (Editor), David N. Rahni (Editor), Edwin H. Kolodny (Editor) An authoritative survey of the cutting-edge imaging technologies available for diagnosing, treating, and discovering the underlying causes of Parkinson's and Alzheimer's disease, epilepsy, and leukodystrophy. The new technologies demonstrated include new sequences for magnetic resonance imaging (MRI), such as magnetization-prepared rapid acquisition gradient echo (MPRAGE); proton magnetic resonance spectroscopy (1H MRS); new tracers for positron emission tomography (PET) and single-photon emission tomography (SPECT), such as tropane analogs and altropane; neuromolecular imaging (NMI) of neurotransmitters directly in brain synapses of epilepsy patients with unique carbon-based electrochemical sensors; and intrinsic optical signal imaging (IOS), useful in diagnosing "spreading epileptiform... |
|
Alcohol-related neurodegeneration and recovery: mechanisms from animal models.: An article from: Alcohol Research & Health by Fulton T. Crews (Author) This digital document is an article from Alcohol Research & Health, published by U.S. Government Printing Office on December 22, 2008. The length of the article is 6898 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: Alcohol-related neurodegeneration and recovery: mechanisms from animal models. Author: Fulton T. Crews Publication: Alcohol Research & Health (Magazine/Journal) Date: December 22, 2008 Publisher: U.S. Government Printing Office Volume: 31 Issue: 4 Page: 377(12) Distributed by Gale, a part of Cengage... | |
|
Advances in Research on Neurodegeneration, I: Definitions, Clinical Features, and Morphology by Donald B. Calne (Author), Reinhard Horowski (Author), Yoshikuni Mizuno (Author), W. H. Poewe (Contributor) | |
|
Pantothenate kinase-associated neurodegeneration: An entry from Thomson Gale's Gale Encyclopedia of Neurological Disorders by Richard Robinson (Author) Targeted to patients, their families and allied health students, The “Gale Encyclopedia of Neurological Disorders” provides in-depth coverage of neurological diseases and disorders, including stroke, multiple sclerosis, Parkinson disease, Tourette Syndrome, Alzheimer's disease, cerebral palsy, vertigo, amnesia and epilepsy. Related topics include communication aids, electric personal assistive mobility devices, medications for treating neurological diseases and conditions, understanding the needs of Alzheimer patient caregivers and more. This two-volume set provides an alternative to resources that either fail to explore neurological disease in any depth and or do so at a level not appropriate for students and general readers. |
| © 2009 BrightSurf.com |